Streetbeat News

Equity Actions

TALS

Talaris Therapeutics, Inc. (TALS) has announced a 1-for-10 reverse stock split of its common stock. The reverse stock split will reduce the number of shares outstanding and is expected to increase the market price per share.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 9:51 pm

CIR

KKR

VICR

Vicor Corporation will be joining the S&P SmallCap 600, replacing CIRCOR International, which is being acquired by KKR & Co. Inc. The transaction is expected to close on October 18.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 9:20 pm

FND

VICR

Floor & Decor Holdings (FND) is set to join the S&P MidCap 400, replacing Vicor Corp. (VICR).

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 9:18 pm

NTBL

Notable Labs has filed for a mixed shelf offering of up to $100 million. The filing allows the company to sell securities in one or more separate offerings with the price, amount, and details to be determined at the time of each offering.

Portfolio Pulse from Charles Gross

October 17, 2023 | 9:04 pm

FFIC

Faraday Future Intelligent Electric Inc. has regained compliance with Nasdaq Listing Rule 5605(b)(1) following the resignation of board member Ke Sun. The company was previously non-compliant due to not having a majority of independent directors. The board has now determined that Ms. Li Han is independent, and reduced the board size from seven to six members, resolving the issue.

Portfolio Pulse from Charles Gross

October 17, 2023 | 8:59 pm

CVS

A significant amount of unusual options activity has been detected for CVS Health (NYSE:CVS), with a majority of investors taking a bearish stance. Of the 11 strange trades detected, 63% were bearish and 36% bullish. The total amount for the 8 puts was $418,270 and for the 3 calls was $102,097. Whales have been targeting a price range from $70.0 to $90.0 for CVS Health over the last 3 months. Evercore ISI Group upgraded its action to Outperform with a price target of $83.

Portfolio Pulse from Benzinga Insights

October 17, 2023 | 8:45 pm

SLB

A significant amount of unusual options activity has been observed for Schlumberger Limited (NYSE:SLB), with a mix of bullish and bearish expectations. Whales have been targeting a price range from $48.0 to $67.5 for SLB over the last 3 months. The price of SLB is currently up 1.33% at $60.24. Analysts from Raymond James and Citigroup maintain their 'Buy' rating on SLB with price targets of $68 and $70 respectively, while Societe Generale downgraded its action to 'Buy' with a price target of $81.

Portfolio Pulse from Benzinga Insights

October 17, 2023 | 8:45 pm

AMAM

Ambrx Biopharma has filed for up to $300 million of securities offerings, according to a recent filing.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 8:31 pm

NUZE

NuZee has commenced a firm commitment underwritten public offering of its common stock. All of the shares are being offered by NuZee itself, however, the terms of the offering have not been disclosed.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 8:23 pm

BAER

Bridger Aerospace has announced a proposed public follow-on offering of $70 million to fund its growth initiatives.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 8:22 pm